Sunday, June 1, 2014

New, earlier E/L requirements for infusion sets?



by Dr Wayland Rushing, Ph.D.

Over the last several months we have had multiple clients come to us after being put on clinical hold for their clinical trials. The formulations are all parenterals, which utilize some kind of infusion set-up (IV bags, infusion pumps, etc). The FDA has requested determination of the extractables and leachables of the contact materials of the infusion sets.

In the past, minimal work was done on these sets and the main issue was compatibility between the drug and the materials (i.e. does the drug adhere/absorb onto the materials). Now the FDA is specifically asking for E&L evaluations of the materials, this includes going beyond the standard USP polymer characterization tests.

I have chatted with a couple of consultants on this and it is new to them as well. This seems to be something rather recent wherein the FDA is actually placing them on clinical hold until the information can be provided. As expected, this is a major concern for the companies being placed on hold, as it can be expensive and puts their development plans into a tailspin until they are able to generate the data.

Unfortunately, generating the data is not a quick and easy fix, but we have a process which seems to be appropriate. We design a study that generates the extractables data and the leachables data on the material in a side-by-side fashion. Allowing for at least a rapid generation of data to correlate to determine if any additional studies are going to be required.

Thursday, May 1, 2014

PTM by MRM: Introducing New Methods to Solve Old Problems


PTM by MRM: A More Efficient Way to Find What You're Looking For


In biotherapeutic development, post-translational modifications (PTMs) can be as elusive as the proverbial needle in a haystack. Traditional methods for identifying and quantifying PTMs involve a painstaking, linear process of individual assays performed one after the other. They require multiple sample preparations and precious time, and findings are often found insufficient by regulators. ABC Laboratories is pleased to introduce a better way.

Tuesday, April 15, 2014

Biosimilars: They Look the Same... But One is a Real Stinker.


Biosimilars Sometimes Behave Differently. The Key is Knowing When it Matters.


Biosimilars by nature look much like their comparator products, but they sometimes behave quite differently. That's because the two products often originate from different cell lines or expression systems. And no matter how hard you strive for parity in the way they're cultured, minor differences in manufacturing can lead to sticky variations in primary amino acid sequence, glycosylation chemical modifications and protein folding issues. The FDA understands biosimilar products sometimes behave differently than their name-brand counterparts. But, they do expect you to understand why those differences occur, and to demonstrate that they have no clinical significance. That's where ABC Laboratories comes in.

Tuesday, April 1, 2014

Agrochemical Product Development: Taking Your Product to New Markets?


Get Post-Registration Support from the Product Development Experts at ABC


These days, it takes roughly 10 years and a development budget with eight zeros to successfully register a new crop protection products. But being first to market is just the beginning. Whether you expand into new territories, seek label expansions or require ongoing environmental monitoring, a trusted development partner is just as important post-registration as it is prior to initial regulatory approval.

Saturday, March 15, 2014

Environmental Assessments: Don't Let Your Environmental Package Be a Regulatory Sticking Point


Seamless E/A Solutions from the Drug Development Experts at ABC


A quality Environmental Assessment (EA) package is a critical component of many new drug product submissions. Not having the right data—or not starting EA investigations soon enough—is an often-underestimated development risk. In fact, these common missteps can lead to lengthy environmental fate or ecotoxicity studies that will delay a drug's approval by up to two years.

ABC helps develop drugs and evaluates their environmental impacts.

Saturday, March 1, 2014

Cytotoxic Drug Development: Choose Your Partner Well


Choose Your Partner Well - Ask ABC


Although regulatory requirements are fundamentally the same for all investigational drugs, working with cytotoxic materials presents unique challenges. Heightened safety procedures and encumbering personal protective equipment can be a drag on timelines—or worse, lead to procedural or analytical errors that compromise data integrity. It's critical to choose a CRO with cytotoxic expertise, yet the field of competent outsourcing partners is small.

Saturday, February 15, 2014

CGMP Radiosynthesis: Will Your CRO Be There When It Counts?


Better Insight, Better Outcomes


Expert 14C radiolabeling for human clinical programs requires extensive training and experience. Having supported radiolabeled studies for more than 30 years, ABC Laboratories was one of the first to produce 14C-labeled API and formulate CTMs under CGMP requirements. Our experienced radiosynthethic chemists have worked with many drug candidates so we can help guide you through the detailed CGMP process. We work in tandem with your chemistry, regulatory, and QA personnel to ensure that a high-quality API or drug product CTM, that meets your specifications, is delivered to the clinic on time.